Table 2 Grade 3 or Higher Treatment-Related Adverse Events

From: Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial

 

Arm A (n = 19)

Arm B (n = 17)

AE type

No. and (%) of Patients Grade 3–5

No. and (%) of Patients Grade 3–5

Overall Highest Grade

3 (15.8)

10 (58.8)

Anemia

0 (0.0)

2 (11.8)

Febrile neutropenia

0 (0.0)

2 (11.8)

Diarrhea

1 (5.3)

3 (17.6)

Mucositis oral

0 (0.0)

1 (5.9)

Nausea

0 (0.0)

2 (11.8)

Vomiting

0 (0.0)

2 (11.8)

Urinary tract infection

1 (5.3)

1 (5.9)

Lymphocyte count decreased

0 (0.0)

2 (11.8)

Neutrophil count decreased

1 (5.3)

2 (11.8)

Platelet count decreased

0 (0.0)

1 (5.9)

White blood cell decreased

0 (0.0)

1 (5.9)

Hypocalcemia

0 (0.0)

1 (5.9)

Hypokalemia

0 (0.0)

1 (5.9)

Hypomagnesemia

0 (0.0)

2 (11.8)

Chronic kidney disease

1 (5.3)

0 (0.0)

Back to article page